Abstract
Currently CEA is the most accurate tumor marker for colorectal cancer. Preoperative determination of this marker can assist staging, treatment planning and in particular postoperative follow-up of colorectal cancer. Postoperative CEA monitoring should be performed every 3 months. Further evaluation for local recurrence or metastatic disease is mandatory if elevated or increasing CEA levels occur after radical surgery. However, present data do not justify using CEA alone for postoperative follow-up and monitoring of adjuvant therapy. Molecular genetic techniques are now increasingly performed to detect genetic alterations that can be used as prognostic markers. In the future, identification and quantification of these genes may even be valuable in defining the susceptibility of healthy individuals for colorectal cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aaltonen LA, Peltomäki P (1994) Genes involved in hereditary nonpolyposis colorectal carcinoma. Anticancer Res 14:1657–1660
Allen Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28:1625–1629
ASCO (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14:2843–2877
Baigrie RJ, Berry AR (1994) Management of advanced rectal cancer. Br J Surg 81:343–352
Benhattar J, Losi L, Chaubert P, Givel JC, Costa J (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104:1044–1048
Bodmer WF, Bailey CJ, Bodmer J, Bussey H J, Ellis A, Gorman P, et al (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328:614–616
Boland CR, Troncale FJ (1984) Familial colonic cancer without antecedent polyposis. Ann Intern Med 100:700–701
Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174–182
Cohen AM, Minsky BD, Schilsky RL (1997) Cancer of the colon. In: De Vita VT, Hellmann S, Rosenberg SA (eds) Principles and practice of oncology, Vol. 1, Lippincott-Raven, Philadelphia, 88:1144–1197
Costanza ME, Das S, Nathanson L, Rule A, Schwartz RS (1974) Proceedings: Carcinoem-bryonic antigen. Report of a screening study. Cancer 33:583–590
Cummings KM, Michalek A, Tidings J, Herrera L, Mettlin C (1986) Results of a public screening program for colorectal cancer. N Y State J Med 86:68–72
Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al (1994) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 77:167
Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104:66–73
Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M (1994) Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12:725–729
Hohenberger P, Schlag P, Gerneth T, Herfarth C (1994) Pre- and postoperative carcinoembryonic antigen determination in hepatic resection fo colorectal metastases. Ann Surg 219:135–143
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221
Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830
Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, et al (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1370
Laurent-Puig P, Olschwang P, Delattre O, Remvikos Y, Asselain B, Melot T, et al (1992) Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102:1136–1141
Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an update review. Gastroenterology 104:1535–1549
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schumann LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328:1365–1371
Morris JB, Stellate TA, Guy BB, Gordon NH, Berger NA (1991) A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg 161:101–105
Neumaier M, Gerhard M, Wagener C (1995) Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 159:43–47
Quentmeier A, Schlag P, Smok M, Herfarth C (1990) Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 16:319–325
Schlag PM, Hünerbein M, Hohenberger P (1996) Surgical resection of metastatic cancer to the liver. Acta Chir Austriaca 28:27–32
Sener SF, Imperato JP, Chmiel J, Fremgen A, Sylvester J (1989) The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA Cancer J Clin 39:50–57
Sidransky D, Tokino T, Hamuten SR, Kinzler KW, Levin B, Frost P, Vogelstein B (1992) Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–105
Steele G Jr, Ellenberg S, Ramming K, O’Connell M, Moertel C, Lessner H, et al (1982) CEA monitoring among patients in multi-institutional adjuvant Gl therapy protocols. Ann Surg 196:162–169
Stevens DP, Mackay IR, Cullen KJ (1975) Carcinoembryonic antigen in an unselected elderly population: a four year follow up. Br J Cancer 32:147–151
Stipa S, Nicolanti V, Botti C, Cosimelli M, Mannella E, Stipa F, et al (1991) Local recurrence after curative resection for colorectal cancer: frequency, risk factors and treatment. J Surg Oncol Suppl 2:155–160
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
Vukasin AP, Ballantyne GH, Flannery JT, Lerner E, Modlin IM (1990) Increasing incidence of cecal and sigmoid carcinoma. Data from the Connecticut Tumor Registry. Cancer 66:2442–2449
Wagner C (1996) Onkologie 2000: die Sicht des klinischen Laboratoriumsmediziners. Onkologe 2:34–38
Ward U, Pimrose JN, Finan PJ, Perren TJ, Selby P, Purves DA, Cooper EH (1993) The use of tumor markers CEA, CA-195 and CA242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67:1132–1135
Wolmark N, Fisher B, Wiand HS, Henry RS, Lerner H, Legault Poisson S, et al (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375–382
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Hünerbein, M. (1998). The Value of Tumor Markers in Colorectal Cancer. In: Schlag, P.M. (eds) Rectal Cancer. Recent Results in Cancer Research, vol 146. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71967-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-71967-7_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71969-1
Online ISBN: 978-3-642-71967-7
eBook Packages: Springer Book Archive